Literature DB >> 16110152

Growth of human mast cells from bone marrow and peripheral blood-derived CD34+ pluripotent progenitor cells.

Arnold S Kirshenbaum1, Dean D Metcalfe.   

Abstract

Human mast cells (HMCs) are derived from a CD34+ pluripotent progenitor cell that is Kit (CD117+), CD13+, Fc epsilonRI- and lacks lineage-specific surface markers. Bone marrow and peripheral blood are two tissue sources available for obtaining CD34+ progenitor cells from which to culture HMCs. CD34+ cells can be isolated and enriched by magnetic separation columns and stored under specific conditions until ready for use. Alternatively, enriched CD34+ cells may be immediately cultured in serum-free culture media containing recombinant human stem cell factor (rhSCF), rhIL-6, and rhIL-3 (first week only). Weekly hemidepletions and the removal of adherent cells and/or debris enables the investigator to obtain HMC cultures, identified by Wright-Giemsa and acidic toluidine blue stains, by 8-10 wk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16110152     DOI: 10.1385/1-59259-967-2:105

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  29 in total

1.  FcepsilonRI-mediated mast cell migration: signaling pathways and dependence on cytosolic free Ca2+ concentration.

Authors:  In Duk Jung; Hyun-Sil Lee; Hoi Young Lee; Oksoon Hong Choi
Journal:  Cell Signal       Date:  2009-07-24       Impact factor: 4.315

2.  Solitary fibrous tumor of soft tissue: a case report and immunohistochemical study.

Authors:  Takashi Yuri; Sayaka Kanematsu; Yen-Chang Lei; Maki Kuwata; Masaharu Oishi; Airo Tsubura
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

3.  Skin microbiome promotes mast cell maturation by triggering stem cell factor production in keratinocytes.

Authors:  Zhenping Wang; Nicholas Mascarenhas; Lars Eckmann; Yukiko Miyamoto; Xiaojun Sun; Toshiaki Kawakami; Anna Di Nardo
Journal:  J Allergy Clin Immunol       Date:  2016-10-14       Impact factor: 10.793

Review 4.  Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation.

Authors:  Steven Maltby; Khashayarsha Khazaie; Kelly M McNagny
Journal:  Biochim Biophys Acta       Date:  2009-02-21

5.  Glycogen synthase kinase 3beta activation is a prerequisite signal for cytokine production and chemotaxis in human mast cells.

Authors:  Madeleine Rådinger; Hye Sun Kuehn; Mi-Sun Kim; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

6.  Knockout of the Trpc1 gene reveals that TRPC1 can promote recovery from anaphylaxis by negatively regulating mast cell TNF-α production.

Authors:  Nevenka Medic; Avanti Desai; Ana Olivera; Joel Abramowitz; Lutz Birnbaumer; Michael A Beaven; Alasdair M Gilfillan; Dean D Metcalfe
Journal:  Cell Calcium       Date:  2013-03-13       Impact factor: 6.817

7.  Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.

Authors:  Geethani Bandara; Michael A Beaven; Ana Olivera; Alasdair M Gilfillan; Dean D Metcalfe
Journal:  Eur J Immunol       Date:  2015-09-09       Impact factor: 5.532

8.  Histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced histamine release is enhanced with SHIP-1 knockdown in cultured human mast cell and basophil models.

Authors:  Jacqueline M Langdon; John T Schroeder; Becky M Vonakis; Anja P Bieneman; Kristin Chichester; Susan M Macdonald
Journal:  J Leukoc Biol       Date:  2008-07-14       Impact factor: 4.962

9.  A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Authors:  Daniel Smrž; Geethani Bandara; Shuling Zhang; Beverly A Mock; Michael A Beaven; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol Methods       Date:  2013-01-25       Impact factor: 2.303

10.  Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue.

Authors:  Joke Patou; Gabriele Holtappels; Karen Affleck; Philippe Gevaert; Claudina Perez-Novo; Paul Van Cauwenberge; Claus Bachert
Journal:  J Inflamm (Lond)       Date:  2009-04-20       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.